Regulatory & Reimbursement
Market Pathways Scorecard: China 2025 Approvals
A graphical look at China device approval trends.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Investors & Dealmaking
2025 Data Is In: Diagnostics Is Having a Renaissance
The diagnostic industry, a perpetual valuation laggard to higher-profile subsectors of the life sciences, with a short-lived exception during the height of COVID-19, may finally be having a moment. Reflecting this optimism, industry experts on a recent Arizona State University online seminar highlighted the success of rising young and increasingly profitable tech-enabled diagnostics companies, labeling them the “Terrific 10,” a moniker that references the tech industry’s “Magnificent 7.”
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
ICYMI
Tech-Enabled Diagnostics Companies Having a Moment
Industry experts on a recent Arizona State University online seminar highlighted the success of rising young and increasingly profitable tech-enabled diagnostics companies, labeling them the “Terrific 10,” a moniker that references the tech industry’s “Magnificent 7.” Excerpted from our recent feature article.